Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial von Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

Volltext

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway von Li, C, Fan, S, Owonikoko, T K, Khuri, F R, Sun, S-Y, Li, R

Volltext

Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis von Wang, B, Xie, M, Li, R, Owonikoko, T K, Ramalingam, S S, Khuri, F R, Curran, W J, Wang, Y, Deng, X

Volltext

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L... von Owonikoko, T.K., Kim, H.R., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S.R., Navarro, A., Rodriguez-Cid, J., Schenker, M., Lee, J.S., Gutierrez, V., Percent, I., Morgensztern, D., Fairchild, J., Baudelet, C., Park, K.

Volltext

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing von Oh, Y-T, Deng, J, Yue, P, Owonikoko, T K, Khuri, F R, Sun, S-Y

Volltext

Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy von Sorrentino, J.A., Lai, A., Weiss, J.M., Dragnev, K.H., Owonikoko, T.K., Adler, S., Antal, J.M., Malik, R.K., Roberts, P.J.

Volltext

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up e... von Owonikoko, T.K., Papadopoulos, K.P., Gil-Martin, M., Moreno, V., Salama, A.K., Calvo, E., Safran, H., González-Martín, A., Aljumaily, R., Mahadevan, D., Niu, J., Kal Mohan, K., Li, J., Stankevich, E., Mathias, M., Lowy, I., Fury, M.G., Babiker, H.M.

Volltext

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurre... von Babiker, H.M., Brana, I., Mahadevan, D., Owonikoko, T.K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K.P., Crittenden, M., Formenti, S., Giralt, J., Garrido Lopez, P., Hervás Morón, A., Mohan, K.K., Fury, M.G., Lowy, I., Stankevich, E., Feng, M., Li, J., Mathias, M.

Volltext

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies von Harvey, R D, Owonikoko, T K, Lewis, C M, Akintayo, A, Chen, Z, Tighiouart, M, Ramalingam, S S, Fanucchi, M P, Nadella, P, Rogatko, A, Shin, D M, El-Rayes, B, Khuri, F R, Kauh, J S

Volltext

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) von Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Volltext

Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy von Dragnev, K.H., Owonikoko, T.K., Csoszi, T., Maglakelidze, M., Beck, J.T., Domine Gomez, M., Lowczak, A., Fulop, A., Hoyer, R.J., Hanna, W., Lowry, P., Aljumaily, R., Chiu, V.K., Bulat, I., Yang, Z., Roberts, P.J., Antal, J.M., Malik, R.K., Morris, S.R., Weiss, J.M.

Volltext

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) von Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Volltext

Lung Adenocarcinoma Staging Based on 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ (AIS) and Minimally Invasive Adenocarcinoma (MIA) von Behera, M, Steuer, C, Gal, A, Owonikoko, T, Khuri, F, Ramalingam, S, Sica, G

Volltext

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC) von Meric-Bernstam, F, Tannir, N, Harding, J, Voss, M, Mier, J, DeMichele, A, Munster, P, Patel, M, Iliopoulos, O, Owonikoko, T, Whiting, S, Orford, K, Bennett, M, Carvajal, R, McKay, R, Fan, A, Telli, M, Infante, J

Volltext

Investigating the Molecular Profile of Lung Adenocarcinoma: A Single-Institution Analysis von Steuer, C, Behera, M, Rossi, M, Fisher, K, Sica, G, Gal, A, Pakkala, S, Pillai, R, Owonikoko, T, Khuri, F, Ramalingam, S

Volltext

Analysis of liver-directed therapies in U.S. cancer patients von Alese, O B, Kim, S, Chen, Z, Ramalingam, S S, Owonikoko, T K, El-Rayes, B F

Volltext

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma von Migden, Michael R, Rischin, Danny, Schmults, Chrysalyne D, Guminski, Alexander, Hauschild, Axel, Lewis, Karl D, Chung, Christine H, Hernandez-Aya, Leonel, Lim, Annette M, Chang, Anne Lynn S, Rabinowits, Guilherme, Thai, Alesha A, Dunn, Lara A, Hughes, Brett G.M, Khushalani, Nikhil I, Modi, Badri, Schadendorf, Dirk, Gao, Bo, Seebach, Frank, Li, Siyu, Li, Jingjin, Mathias, Melissa, Booth, Jocelyn, Mohan, Kosalai, Stankevich, Elizabeth, Babiker, Hani M, Brana, Irene, Gil-Martin, Marta, Homsi, Jade, Johnson, Melissa L, Moreno, Victor, Niu, Jiaxin, Owonikoko, Taofeek K, Papadopoulos, Kyriakos P, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G

Volltext

P38.01 p40 and p63 Immunohistochemistry in the Diagnostic Consideration of NUT Carcinoma in the Lung von Roe, C., Hanley, K., Schneider, F., Owonikoko, T., Sica, G.

Volltext

P1.12A.09 A Phase 1b Study of the MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination with Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer von Steuer, C., Carlisle, J., Leal, T., Ardeshir, F., Holmes, M., Schneider, F., Chen, Z., Switchenko, J., Ross, J., Selvagi, G., Owonikoko, T., ramalingam, s.

Volltext

Mature tertiary lymphoid structures in lung adenocarcinoma are associated with better progression free survival von Obeng, R, Parihar, V, Alexis, D, Behera, M, Owonikoko, T, Pillai, R, Ramalingam, S, Sica, G, Ahmed, R

Volltext